Merit Medical (MMSI) Q4 2025: Operating Margin Rises 138bps as Portfolio Shift Accelerates
Margin expansion and disciplined portfolio management defined Merit Medical’s fourth quarter, as the company outperformed on revenue and profitability while executing a divestiture to sharpen its growth focus. Continued execution on product innovation and M&A integration are setting the stage for 2026, but tariff headwinds and OEM volatility remain key watchpoints.
Summary
- Margin Expansion Drives Upside: Mix shift, pricing, and cost discipline propelled operating margin to a record level.
- Portfolio Streamlining in Focus: Divestiture of low-margin dual cap line reallocates resources toward higher-growth, higher-margin categories.
- Strategic Execution Faces Tariff and OEM Risks: 2026 outlook balances growth with caution on tariffs and customer inventory dynamics.
Performance Analysis
Merit Medical delivered broad-based revenue growth in Q4, with total revenue up double digits year-over-year, led by strong performances in both the cardiovascular and endoscopy segments. Cardiovascular, which accounts for the majority of sales, grew 9% on strength in cardiac and peripheral intervention categories. Cardiac intervention sales were up 21%, boosted by new product launches and continued demand in electrophysiology (EP), cardiac rhythm management (CRM), and access products. Peripheral intervention advanced 13%, with radar localization and delivery systems up over 25% and representing nearly half of PI growth.
Gross margin reached a historic high, up 103 basis points, as product and geographic mix, pricing improvements, and ongoing cost initiatives offset tariff headwinds. Operating margin expanded 138 basis points to 21%, while free cash flow set a quarterly record, reflecting both profit growth and improved working capital management. Notably, OEM (original equipment manufacturing, contract manufacturing for other medical device companies) sales declined 15% in Q4, with U.S. demand impacted by customer inventory destocking and international demand affected by macro softness, especially in China. Despite this, OEM grew 2% for the full year, slightly above initial guidance.
- Cardiac and Peripheral Intervention Outperformance: New products and robust demand in high-growth procedure categories fueled segment gains.
- OEM Volatility Emerges: Inventory destocking and macro headwinds weighed on OEM, a typically stable but lower-margin contributor.
- Free Cash Flow Strength: Record quarterly and annual free cash flow enabled continued investment in capex and strategic initiatives.
International sales grew 6% in Q4, with EMEA (Europe, Middle East, Africa) up 12% constant currency and APAC (Asia-Pacific) up 3%, but China declined in line with expectations due to volume-based purchasing pressures. The company’s diversified global footprint remains a key buffer against regional volatility.
Executive Commentary
"Our constant currency growth in Q4 was driven by 6.6% organic constant currency growth in Q4, which modestly exceeded the high end of the range assumed in our guidance and contributions from our acquisitions, which also exceeded the high end of our expectations."
Martha Aronson, President and CEO
"It's really just more of the same, right? So, you know, continue to be focused on mix, whether that's new R&D projects, or acquisitions, pushing the geography, making sure that we continue our SKU rationalization process. And just, you know, really throw the kitchen sink at the gross margin."
Raul Parra, Chief Financial Officer
Strategic Positioning
1. Portfolio Optimization and Divestiture
The sale of the dual cap product line, a low-margin critical care offering, for $28 million is a clear signal of Merit’s focus on higher-margin, higher-growth categories. The divestiture is expected to free up manufacturing and commercial resources, with management emphasizing redeployment toward more scalable product lines. The move also creates a 140 basis point headwind to reported 2026 growth, but is expected to be margin accretive longer term.
2. Innovation Pipeline and Platform Strategy
Product innovation remains a core growth lever, with 10% of 2025 revenue growth in cardiac and peripheral intervention coming from products launched during the year. The company is now organizing around “platforms” that combine foundational products (access/enabling) and therapeutic products (disease treatment), with foundational products representing two-thirds of revenue (6% CAGR, compound annual growth rate) and therapeutic products one-third (19% CAGR over three years). This approach is designed to deepen customer penetration and support full-line supplier status in key procedure categories.
3. M&A and Capital Allocation Discipline
Leadership reiterated a commitment to both tuck-in and potentially larger M&A, but within disciplined strategic and financial guardrails. Acquisitions remain focused on filling gaps in both foundational and therapeutic portfolios, with cross-functional platform teams tasked with identifying and evaluating targets. The 2025 acquisition contributions exceeded expectations, and available borrowing capacity of nearly $700 million provides flexibility for future deals.
4. Global Diversification and Geographic Execution
Roughly 40% of revenue is generated outside the U.S., providing resilience against regional slowdowns. While China remains pressured by volume-based procurement and macro factors, EMEA and other regions delivered above-average growth. The company continues to invest in international commercial infrastructure and regulatory compliance, with MDR (Medical Device Regulation, EU compliance) costs declining as projects near completion.
5. Tariff and Cost Management
Tariffs remain a material headwind, with a $15 million impact assumed in 2026 guidance, up from $9 million in 2025. Management is actively pursuing cost mitigation through supply chain optimization, product mix, and price realization, but further tariff or retaliatory actions could alter the outlook. The company’s “kitchen sink” approach to gross margin improvement includes SKU rationalization, manufacturing efficiency, and strategic pricing.
Key Considerations
Merit Medical’s Q4 results underscore a business at an operational and strategic inflection—balancing robust margin expansion and innovation with external headwinds and internal realignment. Investors should weigh the following:
Key Considerations:
- Tariff Drag Is Real: Tariff costs are a persistent margin headwind, with further policy changes possible after the recent Supreme Court decision.
- OEM Growth Volatility: Inventory destocking and macro softness in OEM highlight the risk of quarter-to-quarter swings, even as management targets mid-to-high single-digit normalized growth.
- Rhapsody Platform Early, but Strategic: The Rhapsody covered stent, Merit’s first PMA (pre-market approval, FDA pathway for high-risk devices) product, is in early innings with a conservative $7 million U.S. revenue target for 2026, reflecting measured optimism amid competitive dynamics.
- Free Cash Flow Supports Investment: Record cash generation enables continued capex, including a new Utah distribution center, and positions the company for opportunistic M&A.
- Seasonality and Q1 Softness: Q1 2026 guidance reflects a dip in organic growth and margin due to seasonality, divestiture headwinds, and OEM/China challenges; full-year guidance remains robust.
Risks
Key risks for Merit Medical include escalating tariff costs, OEM demand volatility, and macroeconomic pressures, particularly in China and other international markets. The divestiture of the dual cap line introduces a near-term growth headwind, while Rhapsody’s ramp remains uncertain amid entrenched competition. Supply chain disruptions and regulatory changes, though moderating, could still impact operating performance. Investors should monitor the impact of further tariff policy changes and the pace of OEM recovery closely.
Forward Outlook
For Q1 2026, Merit Medical guided to:
- Total revenue of $375–$380 million (6%–7% YoY GAAP growth; 3%–5% constant currency)
- Non-GAAP operating margin of 16.7%–18.5% (down from 19.3% last year)
- Non-GAAP EPS of $0.77–$0.87 (vs. $0.86 last year)
For full-year 2026, management provided:
- Total GAAP revenue growth of 6%–8%, constant currency organic growth of 4.5%–6%
- Non-GAAP operating margin of 20.6%–21%
- Non-GAAP EPS growth of 5%–8%
- Free cash flow of at least $200 million (with $90 million in capex planned)
Management highlighted:
- Platform-based innovation and targeted M&A as key growth drivers
- Continued focus on gross margin through mix, cost, and portfolio actions
- Disciplined capital allocation and readiness for larger M&A if strategically justified
Takeaways
Merit Medical’s Q4 capped a year of outperformance, with margin gains and free cash flow well ahead of plan, even as OEM and China presented near-term challenges.
- Portfolio Moves Support Long-Term Margin: The dual cap divestiture and focus on scalable platforms should drive higher-margin growth over time.
- Execution Strength Offsets Headwinds: Innovation, operational discipline, and global diversification position the company to manage through tariff and OEM volatility.
- 2026 Watchpoints: Investors should track Q1 softness, the pace of Rhapsody adoption, and the impact of further tariff or regulatory changes on both top and bottom line.
Conclusion
Merit Medical exits 2025 with strong operational momentum and a sharpened portfolio, but faces a more complex macro and regulatory environment in 2026. Margin expansion and disciplined capital deployment are clear positives, while tariff escalation and OEM swings bear close monitoring.
Industry Read-Through
Merit’s results reinforce several industry-wide themes: margin expansion in medtech increasingly relies on mix management, targeted M&A, and portfolio pruning rather than pure volume growth. The company’s experience with tariffs provides a cautionary signal for peers with global supply chains, especially as U.S. policy risk rises. OEM volatility and inventory destocking are emerging as sector-wide issues, and the measured approach to new product launches like Rhapsody reflects a shift toward disciplined, data-driven commercialization in competitive device markets. Investors should look for similar strategies and risks among diversified device peers facing comparable macro and regulatory headwinds.